Akinobu Gotoh
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Akinobu Gotoh has a total of 99 co-authors. Here are the top co-authors by number of shared publications:
S Kamidono
16 shared publicationsS Arakawa
12 shared publications- Toshiro Shirakawa
Division of Advanced Medical Science, Kobe University Graduate School of Science, Technology and Innovation, Kobe 650-0017, Japan
10 shared publications H Okada
9 shared publications- Isao Hara
Department of Urology, Kobe University School of Medicine, Kobe, Japan
9 shared publications - Kazuo Gohji
Department of Urology, Kobe University School of Medicine
7 shared publications
Latest Publications
- Open Access
- 1 June 2006
- Published by Wiley in International Journal of Urology
- Vol. 13 (6) , 834-837
Progress report on phase I/II clinical trial of Ad‐OC‐TK plus VAL therapy for metastatic or locally recurrent prostate cancer: Initial experience at Kobe University
Abstract There is no effective therapy for hormone‐refractory prostate cancer and a novel therapeutic modality, such as a gene therapy, should be actively pursued. Previously, Gardner and Chung conducted a phase I clinical trial of Ad‐OC‐TK (recombinant adenoviral vector containing osteocalcin promoter‐driven herpes simplex virus thymidine kinase gene) plus VAL (valacyclovir) for the treatment of hormone‐refractory prostate cancer at the University of Virginia. We report on our ongoing phase I/II clinical trial of Ad‐OC‐TK plus VAL for the treatment of advanced prostate cancer at the Kobe University Hospital, Japan.
- 1 June 2006
- Published by Wiley in International Journal of Urology
- Vol. 13 (6) , 834-837
Open AccessProgress report on phase I/II clinical trial of Ad‐OC‐TK plus VAL therapy for metastatic or locally recurrent prostate cancer: Initial experience at Kobe University
Abstract There is no effective therapy for hormone‐refractory prostate cancer and a novel therapeutic modality, such as a gene therapy, should be actively pursued. Previously, Gardner and Chung conducted a phase I clinical trial of Ad‐OC‐TK (recombinant adenoviral vector containing osteocalcin promoter‐driven herpes simplex virus thymidine kinase gene) plus VAL (valacyclovir) for the treatment of hormone‐refractory prostate cancer at the University of Virginia. We report on our ongoing phase I/II clinical trial of Ad‐OC‐TK plus VAL for the treatment of advanced prostate cancer at the Kobe University Hospital, Japan.
- 1 March 2005
- Published by Springer Nature in Clinical and Experimental Medicine
- Vol. 4 (4) , 196-201
Rapid detection and differentiation of Gram-negative and Gram-positive pathogenic bacteria in urine using TaqMan probe
Urinary tract infection has been shown to be quite complicated and often difficult to diagnose and treat. For appropriate diagnosis, it is very important to find the correct Gram stain classification as soon as possible, especially in severe cases where there is a possibility of severe sepsis developing. In order to solve this problem, we developed a new method to detect a Gram stain of bacteria obtained from 1 ml of urine from urinary tract infection patients using a consensus real-time PCR protocol with a TaqMan probe that allows detection of spiked bacterial 16S DNA from urine. We extracted DNA of 55 urine samples obtained from patients with complicated urinary tract infection and at the same time performed urine culture testing. After DNA extraction, they were subjected to real-time PCR using a TaqMan discrimination system. Sixteen kinds of bacteria were cultured from the urine culture testing. Of these bacteria, eight were classified as Gram-positive bacteria and the other eight were classified as Gram-negative bacteria. Of the 55 samples, the TaqMan technique result showed 27 samples that were classified as Gram-negative bacteria; 11 samples that were Gram-positive, 10 that included both Gram-negative and -positive bacteria, and 7 that showed no amplification. The classifications of all samples corresponded exactly to those determined by urine culture testing. The present genotyping method of real-time PCR using a TaqMan discrimination system could be applied to the rapid detection of Gram-positive or -negative bacteria in urine of urinary tract infection patients. This assay can differentiate those species tested, but whether the presence of other (untested) bacteria could lead to misinterpretation is unknown. For further investigation, it is important to test other (untested) bacteria in the near future.
- 1 March 2005
- Published by Springer Nature in Clinical and Experimental Medicine
- Vol. 4 (4) , 196-201
Rapid detection and differentiation of Gram-negative and Gram-positive pathogenic bacteria in urine using TaqMan probe
Urinary tract infection has been shown to be quite complicated and often difficult to diagnose and treat. For appropriate diagnosis, it is very important to find the correct Gram stain classification as soon as possible, especially in severe cases where there is a possibility of severe sepsis developing. In order to solve this problem, we developed a new method to detect a Gram stain of bacteria obtained from 1 ml of urine from urinary tract infection patients using a consensus real-time PCR protocol with a TaqMan probe that allows detection of spiked bacterial 16S DNA from urine. We extracted DNA of 55 urine samples obtained from patients with complicated urinary tract infection and at the same time performed urine culture testing. After DNA extraction, they were subjected to real-time PCR using a TaqMan discrimination system. Sixteen kinds of bacteria were cultured from the urine culture testing. Of these bacteria, eight were classified as Gram-positive bacteria and the other eight were classified as Gram-negative bacteria. Of the 55 samples, the TaqMan technique result showed 27 samples that were classified as Gram-negative bacteria; 11 samples that were Gram-positive, 10 that included both Gram-negative and -positive bacteria, and 7 that showed no amplification. The classifications of all samples corresponded exactly to those determined by urine culture testing. The present genotyping method of real-time PCR using a TaqMan discrimination system could be applied to the rapid detection of Gram-positive or -negative bacteria in urine of urinary tract infection patients. This assay can differentiate those species tested, but whether the presence of other (untested) bacteria could lead to misinterpretation is unknown. For further investigation, it is important to test other (untested) bacteria in the near future.
- 1 January 2005
- Published by Elsevier in Journal of Infection and Chemotherapy
- Vol. 11 (5) , 226-230
Presence of a mutation in ponA1 of Neisseria gonorrhoeae in numerous clinical samples resistant to various β-lactams and other, structurally unrelated, antimicrobials
- 1 January 2005
- Published by Elsevier in Journal of Infection and Chemotherapy
- Vol. 11 (5) , 226-230
Presence of a mutation in ponA1 of Neisseria gonorrhoeae in numerous clinical samples resistant to various β-lactams and other, structurally unrelated, antimicrobials
- Open Access
- 1 July 2004
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 10 (13) , 4342-4348
A Cox-2 Promoter-Based Replication-Selective Adenoviral Vector to Target the Cox-2-Expressing Human Bladder Cancer Cells
Purpose: Cyclooxygenase-2 (Cox-2), an enzyme that catalyzes the synthesis of prostaglandins, is overexpressed in a variety of premalignant and malignant conditions, including urinary bladder cancer. In the present study, we examined the feasibility of using Cox-2 promoter-based replication-selective adenovirus for targeting bladder cancer cells that express Cox-2 transcriptional activity. Experimental Design: A series of human cancer cell lines, including three bladder cancer cell lines (KK47, T24, and 5637), were evaluated for their Cox-2 and CAR (the Coxsackievirus and adenovirus receptor) mRNA expression levels by quantitative real-time PCR. AdE3-cox2–327, a replication-selective adenovirus in which the expression of E1a is controlled by the Cox-2 promoter, was generated, and its tissue-specific activity was tested in vitro and in vivo. Results: Three bladder cancer cell lines express higher levels of Cox-2 mRNA than does the human prostate cancer cell line PC3, the primary cultured human benign prostatic fibroblast, PF cells, and the human colon cancer cell line Colo320. Relatively higher expression of CAR mRNA was detected in the KK47, 5637, respectively, and Colo320 than in the T24, PC-3, and PF cells. In vitro assays revealed significant growth suppression of both Cox-2- and CAR-expressing bladder cancer cells KK47 and 5637 in comparison with the other cells that lack Cox-2 expression and/or CAR expression. Conclusions: The present study demonstrated both specificity and efficacy of AdE3-cox2–327, a selectively replicated adenovirus, toward the Cox-2-expressing bladder cancer cells in vitro and in vivo. We also found that CAR expression in the target cancer cells is an important factor for the efficacy of selectively replicated adenovirus-based gene therapy.
- 1 July 2004
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 10 (13) , 4342-4348
Open AccessA Cox-2 Promoter-Based Replication-Selective Adenoviral Vector to Target the Cox-2-Expressing Human Bladder Cancer Cells
Purpose: Cyclooxygenase-2 (Cox-2), an enzyme that catalyzes the synthesis of prostaglandins, is overexpressed in a variety of premalignant and malignant conditions, including urinary bladder cancer. In the present study, we examined the feasibility of using Cox-2 promoter-based replication-selective adenovirus for targeting bladder cancer cells that express Cox-2 transcriptional activity. Experimental Design: A series of human cancer cell lines, including three bladder cancer cell lines (KK47, T24, and 5637), were evaluated for their Cox-2 and CAR (the Coxsackievirus and adenovirus receptor) mRNA expression levels by quantitative real-time PCR. AdE3-cox2–327, a replication-selective adenovirus in which the expression of E1a is controlled by the Cox-2 promoter, was generated, and its tissue-specific activity was tested in vitro and in vivo. Results: Three bladder cancer cell lines express higher levels of Cox-2 mRNA than does the human prostate cancer cell line PC3, the primary cultured human benign prostatic fibroblast, PF cells, and the human colon cancer cell line Colo320. Relatively higher expression of CAR mRNA was detected in the KK47, 5637, respectively, and Colo320 than in the T24, PC-3, and PF cells. In vitro assays revealed significant growth suppression of both Cox-2- and CAR-expressing bladder cancer cells KK47 and 5637 in comparison with the other cells that lack Cox-2 expression and/or CAR expression. Conclusions: The present study demonstrated both specificity and efficacy of AdE3-cox2–327, a selectively replicated adenovirus, toward the Cox-2-expressing bladder cancer cells in vitro and in vivo. We also found that CAR expression in the target cancer cells is an important factor for the efficacy of selectively replicated adenovirus-based gene therapy.
- Open Access
- 4 May 2004
- Published by Wiley in International Journal of Urology
- Vol. 11 (5) , 257-263
Long-term outcome of postoperative interferon-alpha adjuvant therapy for non-metastatic renal cell carcinoma
- 4 May 2004
- Published by Wiley in International Journal of Urology
- Vol. 11 (5) , 257-263
Open AccessLong-term outcome of postoperative interferon-alpha adjuvant therapy for non-metastatic renal cell carcinoma
- Open Access
- 23 July 2003
- Published by Wiley in BJU International
- Vol. 92 (3) , 314-318
The growth inhibitory effect of p21 adenovirus on androgen‐dependent and ‐independent human prostate cancer cells
OBJECTIVE: To assess the potential of p21 as a gene therapy treatment for prostate cancer, by introducing p21 into both androgen‐dependent (AD) and ‐independent (AI) human prostate cancer cell lines via a recombinant adenoviral vector, Ad5CMV‐p21, carrying human p21 cDNA. MATERIALS AND METHODS: The LNCaP, DU145 and PC‐3 human prostate cancer cell lines were cultured and infected with Ad5CMV‐p21. Cell growth, cell‐cycle progression and tumorigenicity were then assessed by thymidine incorporation into cellular DNA, and cell number, flow cytometry, and tumour growth after inoculating the cells into nude mice. RESULTS: Growth was inhibited in Ad5CMV‐p21 viral‐infected AD and AI prostate cancer cells. The effects were dose‐dependent, regardless of the androgen status of the cell lines. Flow cytometric analysis showed that Ad5CMV‐p21 arrested cell‐cycle progression at G1/S with no appreciable effect on the levels of apoptotic cells. The tumorigenicity of cancer cells infected with Ad5CMV‐p21 was greatly reduced in athymic mice. CONCLUSIONS: These results suggest that Ad5CMV‐p21 may be a new therapeutic agent for human prostate cancer gene therapy.
- 23 July 2003
- Published by Wiley in BJU International
- Vol. 92 (3) , 314-318
Open AccessThe growth inhibitory effect of p21 adenovirus on androgen‐dependent and ‐independent human prostate cancer cells
OBJECTIVE: To assess the potential of p21 as a gene therapy treatment for prostate cancer, by introducing p21 into both androgen‐dependent (AD) and ‐independent (AI) human prostate cancer cell lines via a recombinant adenoviral vector, Ad5CMV‐p21, carrying human p21 cDNA. MATERIALS AND METHODS: The LNCaP, DU145 and PC‐3 human prostate cancer cell lines were cultured and infected with Ad5CMV‐p21. Cell growth, cell‐cycle progression and tumorigenicity were then assessed by thymidine incorporation into cellular DNA, and cell number, flow cytometry, and tumour growth after inoculating the cells into nude mice. RESULTS: Growth was inhibited in Ad5CMV‐p21 viral‐infected AD and AI prostate cancer cells. The effects were dose‐dependent, regardless of the androgen status of the cell lines. Flow cytometric analysis showed that Ad5CMV‐p21 arrested cell‐cycle progression at G1/S with no appreciable effect on the levels of apoptotic cells. The tumorigenicity of cancer cells infected with Ad5CMV‐p21 was greatly reduced in athymic mice. CONCLUSIONS: These results suggest that Ad5CMV‐p21 may be a new therapeutic agent for human prostate cancer gene therapy.
- 1 December 2002
- Published by Oxford University Press (OUP) in Journal of Pharmacy and Pharmacology
- Vol. 54 (12) , 1645-1650
Inhibition of urinary bladder motility by a spinal action of U-50488H in rats
We examined the effect of a kappa agonist, U‐50488H, upon the bladder motility of anaesthetized rats. The frequency of distension‐induced rhythmic bladder contractions was reduced by the intravenous (10 mg kg−1) or intrathecal (10–100 μg) administration of U‐50488H. The effect of intravenous U‐50488H was inhibited by pre‐treatment with nor‐binaltorphimine (10 mg kg−1, s.c.). The inhibition of bladder contractions by intrathecal U‐50488H (30 μg) was eliminated with the concomitant use of nor‐binaltorphimine (10 mg kg−1, s.c.), and diminished by reserpine (4 mg kg−1, i.p.), yohimbine (10 μg, i.t.) or methysergide (20 μg, i.t.). The amplitude of bladder contractions induced by an electrical stimulation of the pontine micturition centre was not inhibited by intrathecal U‐50488H (30 and 100 μg). These results suggested that a kappa agonist could inhibit micturition reflex as well as other opioids, and at least part of the inhibition was due to the diminishment of bladder sensation based on the activation of the descending monoaminergic systems through the spinal kappa‐opioid receptors.
- 1 December 2002
- Published by Oxford University Press (OUP) in Journal of Pharmacy and Pharmacology
- Vol. 54 (12) , 1645-1650
Inhibition of urinary bladder motility by a spinal action of U-50488H in rats
We examined the effect of a kappa agonist, U‐50488H, upon the bladder motility of anaesthetized rats. The frequency of distension‐induced rhythmic bladder contractions was reduced by the intravenous (10 mg kg−1) or intrathecal (10–100 μg) administration of U‐50488H. The effect of intravenous U‐50488H was inhibited by pre‐treatment with nor‐binaltorphimine (10 mg kg−1, s.c.). The inhibition of bladder contractions by intrathecal U‐50488H (30 μg) was eliminated with the concomitant use of nor‐binaltorphimine (10 mg kg−1, s.c.), and diminished by reserpine (4 mg kg−1, i.p.), yohimbine (10 μg, i.t.) or methysergide (20 μg, i.t.). The amplitude of bladder contractions induced by an electrical stimulation of the pontine micturition centre was not inhibited by intrathecal U‐50488H (30 and 100 μg). These results suggested that a kappa agonist could inhibit micturition reflex as well as other opioids, and at least part of the inhibition was due to the diminishment of bladder sensation based on the activation of the descending monoaminergic systems through the spinal kappa‐opioid receptors.
- Open Access
- 1 January 2002
- Published by Wiley in BJU International
- Vol. 89 (1) , 10-13
Health-related quality of life after radical cystectomy for bladder cancer: a comparison of ileal conduit and orthotopic bladder replacement
- 1 January 2002
- Published by Wiley in BJU International
- Vol. 89 (1) , 10-13
Open AccessHealth-related quality of life after radical cystectomy for bladder cancer: a comparison of ileal conduit and orthotopic bladder replacement
- 1 November 2001
- Vol. 47 (11) , 829-32
[Prospects for molecular research in urological oncology: gene therapy].
The recent great advances in genetic engineering are now making possible the identification and isolation of the trigger genes of many hereditary illnesses, and the clarification of the relevant molecular mechanisms. The idea that if the genetic abnormalities responsible for illness could be established at a DNA level, treatment at the genetic level repairing damaged genes or supplying absent ones would also be possible was the incentive for the recent boom in gene therapy. Clinical research into gene therapy began in 1990 and currently over 3,000 patient cases are being studied. Some 70% of these are cancer patients. This is not simply because such patients are relatively numerous, but is also a sign of the wish, held earnestly by many researchers and clinicians as well as cancer patients and their families, to at last overcome this intractable disease. Gene therapy, so far conducted mainly in the United States, has hitherto not lived up to initial expectations in its concrete results. The reason for this results mainly in technical factors, such as the rate of success in implanting genes into target cells, the rate of successful expression of the implanted genes, and the successful achievement of specific expression at the target site. Gene therapy in the form of clinical research into renal cancer and lung cancer is now under way in Japan. It is too early at this stage to evaluate this work, but the present paper takes this opportunity to give an outline of gene therapy, and to examine its current state, future prospects and problem areas with particular reference to cancer.
- 1 November 2001
- Vol. 47 (11) , 829-32
[Prospects for molecular research in urological oncology: gene therapy].
The recent great advances in genetic engineering are now making possible the identification and isolation of the trigger genes of many hereditary illnesses, and the clarification of the relevant molecular mechanisms. The idea that if the genetic abnormalities responsible for illness could be established at a DNA level, treatment at the genetic level repairing damaged genes or supplying absent ones would also be possible was the incentive for the recent boom in gene therapy. Clinical research into gene therapy began in 1990 and currently over 3,000 patient cases are being studied. Some 70% of these are cancer patients. This is not simply because such patients are relatively numerous, but is also a sign of the wish, held earnestly by many researchers and clinicians as well as cancer patients and their families, to at last overcome this intractable disease. Gene therapy, so far conducted mainly in the United States, has hitherto not lived up to initial expectations in its concrete results. The reason for this results mainly in technical factors, such as the rate of success in implanting genes into target cells, the rate of successful expression of the implanted genes, and the successful achievement of specific expression at the target site. Gene therapy in the form of clinical research into renal cancer and lung cancer is now under way in Japan. It is too early at this stage to evaluate this work, but the present paper takes this opportunity to give an outline of gene therapy, and to examine its current state, future prospects and problem areas with particular reference to cancer.
- 1 July 2001
- Vol. 47 (7) , 453-8
Long-term results of neoadjuvant hormonal therapy prior to radical prostatectomy in patients with clinically localized prostate cancer: biochemical and pathological effects.
The objective of this study was to evaluate the long-term biochemical and pathological effects induced by neoadjuvant hormonal therapy (NHT) in patients with clinically localized disease. Between March 1993 and May 1997, 24 patients with clinically localized prostate cancer received NHT for 3 to 11 months (median: 5 months) using luteinizing hormone-releasing hormone analogue prior to radical prostatectomy and pelvic lymphadenectomy. The clinical stage was T1 in 1 patient, T2 in 17 and T3 in 6, the pretreatment serum prostate-specific antigen (PSA) value was < or = 10 ng/ml in 5 patients, 10 to 20 ng/ml in 4 and > 20 ng/ml in 15 (mean: 34.7 micrograms/l), and the Gleason score was < or = 4 in 9 patients, 5 to 7 in 11 and > 8 in 3. The mean prostate specific antigen (PSA) value 3 months after NHT had reduced below 2 ng/ml in 18 of the 24 patients (67%), and finally decreased by an average of 95% (i.e., 1.9 ng/ml) prior to surgery. The pathological stage was pT0 in 2 patients, pT2 in 10 and pT3 in 12. The incidence of organ-confined disease (OCD) was significantly higher in patients with clinical stage T1 or T2a than with T2b or T3, with pretreatment PSA values < or = 10 ng/ml than with PSA values > 10 ng/ml, and with PSA values < or = 2 than with PSA values > 2 at 3 months after NHT; in contrast, the Gleason score had no significant impact on the rate of OCD. After a median follow-up of 49 months (range 34 to 85 months), 6 patients (25%) had a recurrence evidenced by rising PSA, and the 3-year recurrence-free survival rate was 79%. These results suggest that NHT appears not to be of significant additional benefit to patients who have a higher clinical T stage, higher pretreatment PSA values and/or in patients whose PSA values do not normalize early in the treatment process.
- 1 July 2001
- Vol. 47 (7) , 453-8
Long-term results of neoadjuvant hormonal therapy prior to radical prostatectomy in patients with clinically localized prostate cancer: biochemical and pathological effects.
The objective of this study was to evaluate the long-term biochemical and pathological effects induced by neoadjuvant hormonal therapy (NHT) in patients with clinically localized disease. Between March 1993 and May 1997, 24 patients with clinically localized prostate cancer received NHT for 3 to 11 months (median: 5 months) using luteinizing hormone-releasing hormone analogue prior to radical prostatectomy and pelvic lymphadenectomy. The clinical stage was T1 in 1 patient, T2 in 17 and T3 in 6, the pretreatment serum prostate-specific antigen (PSA) value was < or = 10 ng/ml in 5 patients, 10 to 20 ng/ml in 4 and > 20 ng/ml in 15 (mean: 34.7 micrograms/l), and the Gleason score was < or = 4 in 9 patients, 5 to 7 in 11 and > 8 in 3. The mean prostate specific antigen (PSA) value 3 months after NHT had reduced below 2 ng/ml in 18 of the 24 patients (67%), and finally decreased by an average of 95% (i.e., 1.9 ng/ml) prior to surgery. The pathological stage was pT0 in 2 patients, pT2 in 10 and pT3 in 12. The incidence of organ-confined disease (OCD) was significantly higher in patients with clinical stage T1 or T2a than with T2b or T3, with pretreatment PSA values < or = 10 ng/ml than with PSA values > 10 ng/ml, and with PSA values < or = 2 than with PSA values > 2 at 3 months after NHT; in contrast, the Gleason score had no significant impact on the rate of OCD. After a median follow-up of 49 months (range 34 to 85 months), 6 patients (25%) had a recurrence evidenced by rising PSA, and the 3-year recurrence-free survival rate was 79%. These results suggest that NHT appears not to be of significant additional benefit to patients who have a higher clinical T stage, higher pretreatment PSA values and/or in patients whose PSA values do not normalize early in the treatment process.